tbuckley/cabot-search huggingface dataset:
GUILLAUME de BAILLOU (1538-1616) CLINICIAN AND EPIDEMIOLOGIST
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PWE-181 Quantitative Assessment Of Global Small Bowel Motility In Chronic Intestinal Pseudo-obstruction And Controls: A Preliminary Study
Authors: SK Butt, A Menys, D Atkinson, A Plumb, S Taylor, N Zarate-Lopez, A Emmanuel
Journal: Gut (2014)

<h3>Introduction</h3> In this preliminary report, we present the initial results of a prospective investigation comparing MRI quantified global small bowel motility in healthy controls and patients with proven clinical and radiological Chronic Intestinal pseudo-obstruction (CIPO). Diagnosis is initially difficult and often delayed, many patients undergoing unnecessary surgical intervention prior to final diagnosis. MRI offers a potential non-invasive modality of diagnosis and monitoring, employing post-processing quantitation of global metrics describing small bowel motility<sup>1</sup>. <h3>Methods</h3> Subject selection: 11 healthy non-smoking volunteers (7 Male, mean age 33[22 to 48]) and 5 CIPO patients (3 Male, mean age 53[32 to 82]) were recruited. CIPO patients stopped any medications that influenced small bowel motility for one week prior to scan including opioids, anti-emetics and anti-diarrhoeals. Study overview: Participants underwent a single MRI motility scan before and immediately after an injection of 0.5 mg IV neostigmine, a cholinomimetic with potent prokinetic action. Statistics: Data normality was assessed using Shapiro-Wilk testing. 1) Baseline motility was compared in CIPO patients and controls. 2) Percent change in motility between baseline and post-neostigmine was compared between groups. Difference in means were tested using Welch’s T-test. <h3>Results</h3> Mean baseline small bowel motility scores in CIPO patients was 0.19AU (range 0.1 to 0.25) and in controls 0.35AU (range 0.275 to 0.37) with a statistically significant difference of 0.17AU, P = 0.0026 (CI 0.09 to 0.23). The mean percent increase in small bowel motility scores in CIPO patients following noestigmine was 29% (95% CI from 19 to 50%) and in controls 10% (range 0 to 34) with a statistically significant difference in groups response to neostigmine of 19%, P = 0.029 (95% CI from 4 to 40%). <h3>Conclusion</h3> This study demonstrated significant differences in both resting and cholinomimetic-induced global motility between CIPO patients and healthy controls. Despite marked bowel distension in the CIPO patients, motility appeared present but reduced compared to controls, and responded to provocation with neostigmine suggesting the bowel still exhibits the expected pro-kinetic effects following pharmacological stimulation. With just five patients this is a preliminary study, nevertheless initial results appear promising and support our ongoing investigation program. <h3>Reference</h3> 1 Menys <i>et al</i>. <i>Global Assessment Radiol</i> 2013;269(2):443-50 2 Odille <i>et al</i>. Qu, UKantitative assessment MRM 2012;68(3):783-93 <h3>Disclosure of Interest</h3> None Declared.
Medial arterial calcification and diabetic neuropathy
Authors: M E Edmonds, J W Laws, P J Watkins
Journal: BMJ (1982)

X-ray examinations of the feet, knees, and hands were performed on 20 diabetics with severe neuropathy and 20 diabetics with no evidence of neuropathy but with a similar mean age and duration of diabetes.All were under 53 years old with no clinical evidence of peripheral vascular disease.Medial arterial calcification was much more common and extensive in the patients with neuro- pathy, occurring in the feet in 15 and in the hands in eight compared with in four (p <0 001) and none (p <0 001) of the controls respectively.Although there was some correlation between calcification and both proteinuria (p <0 05) and proliferative retinopathy (p <0 02), the association between calcification and neuropathy (p <0 001) was much stronger.Neuropathy, with sympathetic denervation of the smooth muscle of the tunica media, may be important in the aetiology of medial arterial calcification.
DANGEROUS SELF-DRUGGING.
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOKS OF MULTIPLE AUTHORSHIP
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dirty diesel
Authors: Robin Russell-Jones
Journal: BMJ (2016)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Dirty diesel Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Improved Prognosis of Crytococcic Meningitis with Amphotericin B Therapy
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transmission of Escherichia coli O157:H7 infection in Minnesota child day-care facilities
Authors: E. A. Belongia
Journal: JAMA (1993)

<h3>Objective.</h3> —<i>Escherichia coli</i>0157:H7 infection can cause hemorrhagic colitis and hemolytic uremic syndrome. Since 1988 the Minnesota Department of Health has carried out surveillance for this infection. To assess the occurrence of person-to-person transmission within day-care facilities, we investigated facilities where an infected child attended after onset of symptoms. <h3>Design.</h3> —Parents of children less than 5 years old with<i>E coli</i>0157:H7 infection were interviewed from July 1988 through December 1989. If the child attended day care after onset, stool cultures were obtained from other children in attendance and their parents were interviewed. If there was presumptive evidence of ongoing<i>E coli</i>0157:H7 transmission in a facility, all preschool children were excluded from attending day-care facilities until two consecutive stool cultures were negative. <h3>Results.</h3> —Sixty-eight cases of<i>E coli</i>0157:H7 infection were identified in Minnesota during the 18-month period, including 29 cases identified through investigations at nine day-care facilities. There was evidence of person-to-person transmission in all nine facilities. The median number of infected children per facility was two (range, two to 18), and the median attack rate was 22% (range, 3% to 38%). The median age of the primary case at each facility was 26 months (range, 12 to 59 months). There was no evidence of further transmission at facilities where children were temporarily excluded until two consecutive stool cultures were negative. <h3>Conclusion.</h3> —Person-to-person transmission of<i>E coli</i>0157:H7 is common when infected preschool children attend day care while symptomatic. The number of unrecognized day-care outbreaks in the United States may be substantial due to the lack of routine testing for this pathogen in stool cultures, the absence of public health surveillance in many regions, and incomplete follow-up of infected children. Temporary exclusion of all children was an effective control strategy in this population, but additional investigations are needed to determine the optimal intervention. (<i>JAMA</i>. 1993;269:883-888)
Specialist training.
Authors: A. Papagiannis
Journal: BMJ (1992)

The evidence to be put forward by Dr Edwin Borman and the Junior Doctors Committee to the chief medical officer's working group on specialist training' does not reflect the true views of junior hospital doctors in training in Britain.At a recent mess meeting at the Royal Liverpool Children's Hospital, Alder Hey, there was overwhelming support for retention of the consultant grade as it now stands.There was widespread concern that a specialist grade would lead to 10-1 5 years as a senior resident doctor.What exactly is Dr Borman and colleagues' mandate in representing the views of
Early antibiotic treatment in acute necrotising pancreatitis
Authors: François Baudin, Yves Ozier, Vesa Sainio, Esko Kemppainen, Reijo Haapiainen, Tom Schröder, Eero Kivilaakso, Ville Valtonen, Pauli Puolakkainen, Gunnar Tydén, Christina Brattström, Anna-Stina Malmborg
Journal: The Lancet (1995)
PRAGUE
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Texas Medical Practice Laws.
Authors: None Doctor
Journal: JAMA (1898)

Chicago, Dec. 28, 1897. <h3>To the Editor:</h3> —Kindly advise me in ourJournalas to laws and regulations of practicing medicine in the State of Texas. <h3>Answer:</h3> A license is issued after examination by a District Board of Medical Examiners. Diplomas confer no right to practice.<i>Vide</i>theJournal, Vol. 22, p. 355.
LIFE INSURANCE EXAMINATION FEES.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Peptic Ulcer
Authors: David T. Monahan
Journal: New England Journal of Medicine (1953)

IT is not uncommon to encounter a middle-aged patient who for a number of years has suffered from ulcer and who, weary of his recurrent trials, seeks relief in surgery. Physicians are now less reluctant to advise surgical treatment of refractive ulcers than they were before the introduction of antibiotics, and it is generally agreed that modern surgical treatment is more effective and less hazardous. Yet many are unaware of the progress in surgical treatment in the past two decades, and it seems appropriate to restate and re-evaluate results so that therapy can be advised in the light of contemporary . . .
Pediatrics
Authors: H. A. Pearson
Journal: JAMA (1994)

As late as the 1980s, serious invasive diseases caused by<i>Haemophilus influenzae</i>type b (Hib), chiefly meningitis and epiglottitis, were important causes of morbidity and mortality in children, especially in infants younger than 15 months. The mortality associated with Hib meningitis was 3% to 6%, and permanent neurological sequelae occurred in 20% to 30% of survivors. This degree of morbidity and mortality was comparable to that observed during the last great epidemics of paralytic poliomyelitis during the 1950s. The first vaccines active against Hib disease were prepared from the Hib capsular polysaccharide polyribosylribitol phosphate (PRP) and introduced in the 1980s. These Hib PRP vaccines were immunogenic and clinically effective in children older than 18 months. However, they elicited little antibody response in infants aged 3 to 17 months, and two thirds of serious invasive Hib disease occurs in infants younger than 18 months. Despite this, in 1985 PRP vaccine administration
Critics Denounce Staffing Jails and Prisons With Physicians Convicted of Misconduct
Authors: A. A. Skolnick
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).
Authors: Thomas Powles, Joshua J Meeks, Matt D. Galsky, Michiel Simon Van Der Heijden, Hiroyuki Nishiyama, Hikmat Al-Ahmadie, Ashok Kumar Gupta, Jiabu Ye, Sarah E. Donegan, Dana C. Ghiorghiu, Salvatore Ferro, James WF Catto
Journal: Journal of Clinical Oncology (2019)

TPS4592 Background: Management of MIBC includes both surgery and systemic therapy. Neoadjuvant, cisplatin-based combination chemotherapy has demonstrated improved pathologic complete response (pCR), event-free survival (EFS), and OS compared with radical cystectomy alone. Many patients still develop recurrence, including progression to metastasis. Novel strategies such as combining chemotherapy and immunotherapy in a neoadjuvant setting and consolidating response post cystectomy in the adjuvant setting may improve clinical outcomes. Durvalumab is a selective, high affinity, engineered human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80. PD-L1 inhibition with durvalumab, in combination with a standard neoadjuvant regimen (G+C), may improve immune-mediated antitumor response and increase the rates of pathologic responses and long-term survival. Methods: NIAGARA (NCT03732677) is a Phase 3, randomized, open-label, multicenter, global study that will enroll ~1050 patients randomized (1:1) to durvalumab and G+C combination (Arm 1) or G+C (Arm 2) as neoadjuvant chemotherapy prior to radical cystectomy. Following radical cystectomy and during adjuvant therapy, patients in Arm 1 will receive durvalumab monotherapy for 8 cycles (8 months); patients in Arm 2 will receive no adjuvant treatment. Patients with resectable MIBC (clinical stage T2N0M0-T4aN0M0) with transitional cell histology planning to undergo a radical cystectomy will be included. Primary endpoints are pCR rates at time of cystectomy following neoadjuvant treatment and EFS. Secondary and exploratory endpoints include proportion of patients who achieve pathologic response &lt;P2 (stages Pa, P1, and carcinoma in situ) at time of cystectomy following neoadjuvant treatment, EFS at 24 months, metastasis-free survival, proportion of patients who undergo cystectomy, and OS at 5 years. Safety, patient-reported outcomes, pharmacokinetics, immunogenicity, and biomarkers will also be assessed. Enrollment opened in Dec 2018. Clinical trial information: NCT03732677.
Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre randomized, vehicle-controlled clinical study
Authors: H. Nakagawa, O. Nemoto, A. Igarashi, T. Nagata
Journal: British Journal of Dermatology (2018)

Atopic dermatitis (eczema) is a chronic, and sometimes debilitating, inflammatory skin disease which causes itching and damaged skin barrier function. Current treatments include topical (applied to the skin) corticosteroids and calcineurin inhibitors such as tacrolimus; unfortunately long‐term use of topical corticosteroids may cause thinning of the skin and tacrolimus can be irritant. Kinases are enzymes that are important to many roles of cells within the body, and the Janus Kinase (JAK) pathway plays a role in inflammation. In recent years, medicines that inhibit this pathway have been developed, with potential benefit in inflammatory skin diseases such as eczema or psoriasis. The authors, based in Tokyo and Hokkaido, Japan, studied the effect of different concentrations (0.5‐3%) of a topical JAK inhibitor, JTE‐052, in adults with moderate to severe atopic dermatitis, compared with the vehicle on its own (the ointment to which the medicine is added), and with 0.1% tacrolimus ointment. They used a modified Eczema Area and Severity Score before and after 4 weeks of treatment to allow them to see how well each of the treatments was working. In the patients using the 3% concentration there was 73% improvement in the score, compared with 12% using the placebo (vehicle) ointment. There was a 62% improvement in the patients using tacrolimus. Even the 3% concentration of JTE‐052 was very well tolerated, without the irritancy and burning seen with tacrolimus, and the patients using JTE‐052 noticed a reduction in itching within a day of starting treatment. The authors conclude that topical use of this JAK inhibitor is effective in the treatment of atopic dermatitis.